Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non–Small‐Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery

[1]  F. Q. Ribeiro.  The meta-analysis , 2017, Brazilian journal of otorhinolaryngology.

[2]  A Vergnenegre,et al.  Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  J. Hoeijmakers,et al.  Understanding nucleotide excision repair and its roles in cancer and ageing , 2014, Nature Reviews Molecular Cell Biology.

[4]  G. Cao,et al.  Associations of Polymorphisms in DNA Repair Genes and MDR1 Gene with Chemotherapy Response and Survival of Non-Small Cell Lung Cancer , 2014, PloS one.

[5]  H. Wan,et al.  Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine. , 2014, Genetics and molecular research : GMR.

[6]  W. Ma,et al.  Pharmacogenetics of DNA repair gene polymorphisms in non-small-cell lung carcinoma patients on platinum-based chemotherapy. , 2014, Genetics and molecular research : GMR.

[7]  Hong-yan Cheng,et al.  Polymorphisms in XPD Gene Could Predict Clinical Outcome of Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer Patients: A Meta-Analysis of 24 Studies , 2013, PloS one.

[8]  B. Solomon,et al.  Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation. , 2013, Clinical lung cancer.

[9]  Lin Xu,et al.  Predictive Value of XPD Polymorphisms on Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis , 2013, PloS one.

[10]  G. Fontanini,et al.  ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin , 2013, British Journal of Cancer.

[11]  J. Soria,et al.  ERCC1 and RRM1: ready for prime time? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Massuti,et al.  Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer , 2012, Cancer Chemotherapy and Pharmacology.

[13]  L. Crinò,et al.  Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  Jing Wu,et al.  Assessment of XPD Lys751Gln and XRCC1 T-77C polymorphisms in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. , 2011, Lung cancer.

[15]  R. Booton,et al.  No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. , 2011, Lung cancer.

[16]  Yi Shi,et al.  Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis , 2011, Medical oncology.

[17]  E. Felip,et al.  Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. , 2011, Lung cancer.

[18]  Yong Song,et al.  ERCC2/XPD Lys751Gln and Asp312Asn Gene Polymorphism and Lung Cancer Risk: A Meta-Analysis Involving 22 Case–Control Studies , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  M. Pincus,et al.  Conformational effects of a common codon 751 polymorphism on the C-terminal domain of the xeroderma pigmentosum D protein , 2009, Journal of carcinogenesis.

[20]  R. Rosell,et al.  Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression , 2009, PloS one.

[21]  S. Z. Abdel‐Rahman,et al.  Single nucleotide polymorphisms of the DNA repair gene XPD/ERCC2 alter mRNA expression , 2007, Pharmacogenetics and genomics.

[22]  R. Rosell,et al.  Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Manal M. Hassan,et al.  The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk. , 2007, Cancer letters.

[24]  P. Vineis,et al.  Human Genome Epidemiology (huge) Review Xrcc3 and Xpd/ercc2 Single Nucleotide Polymorphisms and the Risk of Cancer: a Huge Review , 2022 .

[25]  R. Booton,et al.  Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum‐based chemotherapy in advanced nonsmall cell lung cancer , 2006, Cancer.

[26]  M. Taron,et al.  Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  D. Campa,et al.  Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. , 2006, Carcinogenesis.

[28]  G. Bepler,et al.  Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. , 2005, Lung cancer.

[29]  M. Taron,et al.  Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  D. Neuberg,et al.  XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  L. Gelbert,et al.  An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines , 2004, Cancer Research.

[32]  G. Bepler,et al.  Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients , 2004, Clinical Cancer Research.

[33]  S. Gasser,et al.  RecQ helicases: multiple roles in genome maintenance. , 2003, Trends in cell biology.

[34]  G. Bepler,et al.  Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer , 2003, Oncogene.

[35]  A. Duncan,et al.  Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. , 2002, Cancer research.

[36]  M. Spitz,et al.  An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. , 2002, Journal of the National Cancer Institute.

[37]  S. Groshen,et al.  A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. , 2001, Cancer research.

[38]  E. Bowman,et al.  Functional significance of XPD polymorphic variants: attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp/Asp genotype. , 2001, Cancer research.

[39]  C. Harris,et al.  Genetic polymorphisms in DNA repair genes and risk of lung cancer. , 2001, Carcinogenesis.

[40]  C I Amos,et al.  Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. , 2001, Cancer research.

[41]  B. Glickman,et al.  Identification of single nucleotide polymorphisms in human DNA repair genes , 2022 .

[42]  R. Parshad,et al.  XPD polymorphisms: effects on DNA repair proficiency. , 2000, Carcinogenesis.

[43]  G. Bepler,et al.  Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1) , 1999, Mammalian Genome.

[44]  I. M. Jones,et al.  Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. , 1998, Cancer research.

[45]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[46]  S. Ren,et al.  Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy. , 2012, Lung Cancer.

[47]  Zhou Hai-yu.  Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression , 2010 .

[48]  N. Hanna,et al.  RRM1 Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non–Small-Cell Lung Cancer , 2008 .